Cargando…
Randomized phase-III study of low-dose cytarabine and etoposide + /− all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia
The aim of this randomized clinical trial was to evaluate the impact of all-trans retinoic acid (ATRA) in combination with non-intensive chemotherapy in older unfit patients (> 60 years) with newly diagnosed NPM1-mutated acute myeloid leukemia. Patients were randomized (1:1) to low-dose chemother...
Autores principales: | Schlenk, R. F., Weber, D., Krzykalla, J., Kindler, T., Wulf, G., Hertenstein, B., Salih, H. R., Südhoff, T., Krauter, J., Martens, U., Wessendorf, S., Runde, V., Tischler, H. J., Bentz, M., Koller, E., Heuser, M., Thol, F., Benner, A., Ganser, A., Döhner, K., Döhner, H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491626/ https://www.ncbi.nlm.nih.gov/pubmed/37684299 http://dx.doi.org/10.1038/s41598-023-41964-y |
Ejemplares similares
-
Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study
por: Schlenk, Richard F., et al.
Publicado: (2020) -
Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia
por: Jaramillo, S, et al.
Publicado: (2017) -
Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine
por: Schlenk, R. F., et al.
Publicado: (2019) -
Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with nucleophosmin1-mutated acute myeloid leukemia receiving gemtuzumab ozogamicin
por: Teich, Katrin, et al.
Publicado: (2021) -
Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation
por: Cocciardi, Sibylle, et al.
Publicado: (2019)